FDA will miss its Nov. 22, 2026 target date for Savara’s molgramostim inhalation solution application; review continues with no new date set
Observed price moves
- SVRA-20.55%10 min after this headline
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.